Management of heart failure

Current Cardiology Reports

Volumn 2, Issue 3, 2000, Pages 221-224

  Le Jemtel, Thierry H ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOFETILIDE; PHENETHYLAMINE DERIVATIVE; RAMIPRIL; SULFONAMIDE;

ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY DISEASE; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL REVASCULARIZATION; PHENETHYLAMINES; RAMIPRIL; RANDOMIZED CONTROLLED TRIALS; SULFONAMIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0034180950     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-000-0072-8     Document Type: Review

References (19)

1. The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000, 324:145-153.
2. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302.
3. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992, 327:685-691.
4. Packer M, Poole-Wilson PA, Armstrong PW, et al. : Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 1999, 100:2312-2318.
5. Berger R, Stanek B, Hulsmann M, et al. : Delayed effects of one-year treatment with low-dose as compared with highdose enalapril on morbidity and mortality of patients with severe heart failure. J Clin Bas Cardiol 1998, 1:19-24.
6. Mancini D, Davis L, Wexler JP, et al. : Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. J Am Coll Cardiol 1987, 10:845-850.
7. Drexler H, Banhardt U, Meinertz T, et al. : Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. Circulation 1989, 79:491-502.
8. Stevenson W, Stevenson LW: Atrial fibrillation in heart failure. N Engl J Med 1999, 341:910-911.
9. Torp-Pedersen C, Moller M, Bloch-Thomsen PE, et al. : Dofetilide in patients with congestive heart failure and left ventricular dysfunction. N Engl J Med 1999, 341:857-865.
10. Pozzoli M, Cioffi G, Traversi E, et al. : Predictors of primary atrial fibrillation and concomitant clinical and hemodynamic changes in patients with chronic heart failure: a prospective study in 344 patients with baseline sinus rhythm. J Am Coll Cardiol 1998, 32:197-204.
11. Dries DL, Exner DV, Gersh BJ, et al. : Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998, 32:695-703.
12. Greenberg B, Chatterjee K, Parmley WW, et al. : The influence of left ventricular filling pressure on atrial contribution to cardiac output. Am Heart J 1979, 98:742-751.
13. Mukharji J, Rehr RB, Hastillo A, et al. : Comparison of atrial contribution to cardiac hemodynamics in patients with normal and severely compromised cardiac function. Clin Cardiol 1990, 13:639-643.
14. Pitt B, Zannad F, Remme WJ, et al. : The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Eng J Med 1999, 341:709-717.
15. Jorde U, Suryadevara V, Hammer A, et al. : Plasma aldosterone levels do not predict degree of angiotensin-converting enzyme inhibition in heart failure patients. J Am Coll Cardiol 1999, 33(suppl):214A.
16. Frazier OH, March RJ, Horvath KA: Transmyocardial revascularization with a carbon dioxide laser in patients with end-stage coronary artery disease. N Engl J Med 1999, 341:1021-1028.
17. Agarwal R, Ajit M, Kurian VM, et al. : Transmyocardial laser revascularization: early results and 1-year follow-up. Ann Thorac Surg 1999, 67:432-436.
18. Cooley DA, Frazier OH, Kadipassaoglu KA, et al. : Transmyocardial laser revascularization: clinical experience with 12-month follow-up. J Thorac Cardiovasc Surg 1996, 111:791-797.
19. Gheorghiade M, Bonow RO: Chronic heart failure in the United States. Circulation 1998, 97:282-289.